Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1-20 of 604 trials

Diabetic Foot Infections: Contezolid Treatment Study

We are studying a new treatment called contezolid for adults with moderate to severe diabetic foot infections. The goal is to see if it is safer and more effective than the current standard treatment, linezolid.

Diabetic Foot Infection≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInfectious Diseases

Ulcerative Colitis: SAR443122 Study

We are testing different doses of SAR443122 in adults with moderate to severe ulcerative colitis to see how well it works and its safety. The study will also look at improvements in symptoms and quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Crohn's Disease: Comparing Biological Therapies After Surgery

We are studying two ways to start biological therapy after surgery for Crohn's disease to see which better prevents disease recurrence. This trial involves adults who have had an ileocolonic resection.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

MOG Antibody Disease: Azathioprine Study

We are testing whether azathioprine can help prevent relapses in adults with MOG antibody-associated disease after their first attack. The study also looks at safety and quality of life for participants.

Anti-Myelin-Associated Glycoprotein Antibodies Positive>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Prostate Cancer: Lutetium-177 vs. Standard Treatments

We are comparing a new treatment called Lutetium-177 with standard medications for men with metastatic hormone-sensitive prostate cancer. The goal is to see which option better delays disease progression and improves survival.

Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Chronic Kidney Disease: Amiloride Treatment Study

We are investigating whether the diuretic amiloride can help protect kidney function in people with chronic kidney disease. The study looks at its effects on kidney health and inflammation.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Arrhythmic Mitral Valve Prolapse: Flecainide and Metoprolol Study

We are studying whether adding flecainide to metoprolol can better reduce irregular heartbeats in patients with arrhythmic mitral valve prolapse. This trial aims to assess the safety and effectiveness of this combination treatment.

Mitral Valve Prolapse>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

High-Risk Prostate Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Early Breast Cancer: Camizestrant vs. Standard Therapy

We are studying whether the new medication camizestrant can better prevent breast cancer recurrence in patients who have completed initial treatment. This trial involves individuals with ER+/HER2- early breast cancer at risk of returning after standard therapy.

ER+/HER2- Early Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Multiple Sclerosis: Rituximab vs. Ocrelizumab Study

We are comparing two treatments for relapsing-remitting multiple sclerosis to see if rituximab is as effective as ocrelizumab in preventing disease activity. This study also examines patient quality of life and other important factors.

Multiple Sclerosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesNeurology

Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

Biliary Atresia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyPediatrics

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Children's Experience After General Anesthesia: Sedation Study

We are examining how different sedative medications impact children's recovery after surgery. The goal is to see if these medications can help reduce anxiety and improve overall comfort.

General Anesthesia and Sedation6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesInternal MedicineOtolaryngologyPediatrics

Diffuse Large B-Cell Lymphoma: Acalabrutinib with R-miniCHOP

We are studying whether adding acalabrutinib to a reduced chemotherapy regimen helps older adults with untreated diffuse large B-cell lymphoma live longer and have better treatment responses. This trial is for those over 60 or 80 years who cannot receive full-dose chemotherapy.

High-Grade B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Acute Myeloid Leukemia: Oral-Azacitidine with Gilteritinib

We are studying a new combination treatment for adults with relapsed or refractory FLT3-mutated acute myeloid leukemia. The goal is to see if this approach improves remission rates and safety compared to current options.

Acute Myeloid Leukaemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Hypertension in Chronic Kidney Disease: Diuretic Treatment Study

We are investigating if a new diuretic-based treatment helps people with moderate to severe chronic kidney disease and uncontrolled hypertension. The goal is to see if it can reduce serious health issues like kidney failure and heart problems.

Chronic Kidney DiseaseUncontrolled Hypertension>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyNephrology

High-Risk Prostate Cancer: THUNDER Trial

We are studying new diagnostic tracers and treatment options for men with high-risk prostate cancer. The goal is to see if these methods improve survival and quality of life compared to standard treatments.

Prostate Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesOncologyUrology

Major Depressive Disorder: Minocycline vs. Celecoxib

We are studying whether minocycline or celecoxib can help patients with Major Depressive Disorder who haven't responded to previous treatments. The trial will compare how well these medications work and how patients respond to them.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPsychiatry